Hubei Biocause Pharmaceutical Working Capital to Net Assets Ratio
Hubei Biocause Pharmaceutical working capital to net assets ratio. Hubei Biocause Pharmaceutical (000627) has a Working Capital to Net Assets ratio of 49.3% as of September 2024. Working capital of CN¥17.75 Billion (current assets of CN¥35.20 Billion minus current liabilities of CN¥17.45 Billion) is measured against net assets of CN¥36.00 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 000627 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hubei Biocause Pharmaceutical (2015–2023)
Working capital to net assets ratio of Hubei Biocause Pharmaceutical from 2015 to 2023. This chart shows how Hubei Biocause Pharmaceutical's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2015 to 2023. As of September 2024, the ratio stands at 49.3%, reflecting working capital of CN¥17.75 Billion against net assets of CN¥36.00 Billion CNY. See Hubei Biocause Pharmaceutical (000627) liquidity interval to measure how many days the company can operate on defensive assets alone.
Hubei Biocause Pharmaceutical Working Capital to Net Assets Ratio by Year (2015–2023)
Hubei Biocause Pharmaceutical working capital to net assets ratio by year from 2015 to 2023. The table below presents the year-by-year Working Capital to Net Assets ratio for Hubei Biocause Pharmaceutical from 2015 to 2023, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 000627 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 77.9% | CN¥26.20 Billion | CN¥33.63 Billion | CN¥50.67 Billion | CN¥24.46 Billion | ▼ -11.7 pp |
| 2022 | 89.6% | CN¥30.99 Billion | CN¥34.60 Billion | CN¥55.98 Billion | CN¥24.99 Billion | ▼ -7.6 pp |
| 2021 | 97.1% | CN¥36.40 Billion | CN¥37.47 Billion | CN¥49.46 Billion | CN¥13.06 Billion | ▼ -26.9 pp |
| 2020 | 124.0% | CN¥42.89 Billion | CN¥34.59 Billion | CN¥50.90 Billion | CN¥8.02 Billion | ▲ +75.3 pp |
| 2019 | 48.7% | CN¥16.72 Billion | CN¥34.35 Billion | CN¥25.16 Billion | CN¥8.43 Billion | ▼ -39.1 pp |
| 2018 | 87.8% | CN¥22.83 Billion | CN¥26.01 Billion | CN¥49.32 Billion | CN¥26.49 Billion | ▲ +25.2 pp |
| 2017 | 62.6% | CN¥16.71 Billion | CN¥26.70 Billion | CN¥26.99 Billion | CN¥10.29 Billion | ▼ -13.8 pp |
| 2016 | 76.3% | CN¥15.57 Billion | CN¥20.40 Billion | CN¥19.38 Billion | CN¥3.81 Billion | ▲ +83.8 pp |
| 2015 | -7.5% | CN¥-133.56 Million | CN¥1.78 Billion | CN¥281.47 Million | CN¥415.04 Million | — |